BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37960718)

  • 1. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
    Ye J; Tian W; Zheng B; Zeng T
    Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.
    Feng Q; Lu H; Wu L
    PLoS One; 2023; 18(9):e0291645. PubMed ID: 37725627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
    Wang T; Han L; Xu J; Guo B
    Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing.
    Chen X; Peng C; Chen Y; Ding B; Liu S; Song Y; Li Y; Sun B; Yang R
    BMC Bioinformatics; 2023 May; 24(1):216. PubMed ID: 37231356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
    Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L
    Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
    Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
    Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
    Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
    Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
    Xu L; Zheng Q; Liu W
    BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
    Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.
    Wei Y; Lan C; Yang C; Liao X; Zhou X; Huang X; Xie H; Zhu G; Peng T
    Sci Rep; 2023 Sep; 13(1):14519. PubMed ID: 37666920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.